Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacol 22: 380-387

Max Planck Institute of Psychiatry, Munich, Germany.
Neuropsychopharmacology (Impact Factor: 7.05). 05/2000; 22(4):380-7. DOI: 10.1016/S0893-133X(99)00095-0
Source: PubMed


Mice with a genetic disruption (knockout) of the multiple drug resistance (Mdr1a) gene were used to examine the effect of the absence of the drug-transporting P-glycoprotein at the blood-brain barrier on the uptake of amitriptyline (AMI) and fluoxetine (FLU) and their metabolites into the brain. One hour after intraperitoneal injection of AMI or FLU, knockout (-/-) and wild-type (+/+) mice were sacrificed and drug concentrations of brain, kidney, liver, testis, and plasma were measured. The plasma concentrations of the AMI metabolites and the brain:spleen ratios of AMI, nortriptyline (NOR), 10-OH-AMI and 10-OH-NOR were significantly higher in the -/- mice, demonstrating that AMI and its metabolites are substrates of the P-glycoprotein and that mdr1a activity at the level of the blood-brain barrier reduces the penetration of these substances into the brain. In contrast, tissue distributions of FLU and its metabolites among the various tissues tested were indistinguishable between groups. The herein reported differences in brain penetration of antidepressant drugs depending on the presence of the mdr1a gene may offer an explanation for differences in the treatment response at a given plasma concentration. Moreover, individual differences in mdr1 gene activity may account for variable response patterns at different episodes and development of therapy resistance.

Download full-text


Available from: Alexander Yassouridis, Jul 09, 2014
    • "The blood was placed in plain tubes and centrifuged at 3000 g for 5 min for separation of serum which was stored at −80 ° until measurement of the levels of F and NF. Mice were then sacrificed and brains were removed, weighed and stored frozen at −80° until analysis[17]. Concentrations of F and NF were measured using the following procedure. Stock standard solutions (1 mg/ml) of F, NF and IS were prepared by dissolving accurately weighed 10.0 mg of each compound in 5 ml of methanol and diluting to 10 ml with the same solvent. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was designed to study potentiation of fluoxetine's antidepressant effect by curcumin or pindolol. Twenty eight groups of mice (n=8) were used in three sets of experiments. In the first set, 9 groups were subjected to the forced swimming test after being treated intraperitoneally with three vehicles, fluoxetine (5 and 20 mg/kg), curcumin (20 mg/kg), pindolol (32 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg). One hour after the test, serum and brain fluoxetine and norfluoxetine levels were measured in mice receiving fluoxetine (5 and 20 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg). In the second set, the test was done after pretreatment with p-chlorophenylalanine. In the third set, the locomotor activity was measured. The immobility duration was significantly decreased in fluoxetine (20 mg/kg), curcumin (20 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg) groups. These decreases were reversed with p-chlorophenylalanine. Fluoxetine and norfluoxetine levels were significantly higher in fluoxetine (20 mg/kg) group with no differences in fluoxetine (5 mg/kg), curcumin+fluoxetine (5 mg/kg) and pindolol+fluoxetine (5 mg/kg) groups. Moreover, drugs failed to alter the locomotor activity indicating absence of central stimulation. In conclusion, curcumin, more than pindolol enhanced the antidepressant effect of a subeffective dose of fluoxetine in mice without increasing its serum or brain levels excluding any pharmacokinetic interaction. Reversal of this potentiation with p-chlorophenylalanine suggests a pharmacodynamic interaction through involvement of presynaptic 5-HT1A receptors.
    No preview · Article · May 2014 · Indian Journal of Pharmaceutical Sciences
  • Source
    • "More than ten years ago, Uhr et al. have started to investigate the influence of the P-glycoprotein (P-gp), a drug efflux pump at the blood-brain barrier which is encoded by the ABCB1 gene, on the penetration of different classes of antidepressant into the brain in a transgenic mouse model. Using those animals deficient of P-gp, they could show that many antidepressants are substrates of the P-gp, among them, for example, widely prescribed compounds such as paroxetine and venlafaxine as well as tricyclic compounds like amitriptyline [41, 42]. They later translated their preclinical findings into the clinic and could finally show that polymorphisms in the ABCB1 gene predict the response to antidepressant treatment in those depressed patients receiving drugs that had previously been identified as substrates of ABCB1 using double-knockout mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Major depression, affecting an estimated 350 million people worldwide, poses a serious social and economic threat to modern societies. There are currently two major problems calling for innovative research approaches, namely, the absence of biomarkers predicting antidepressant response and the lack of conceptually novel antidepressant compounds. Both, biomarker predicting a priori whether an individual patient will respond to the treatment of choice as well as an early distinction of responders and nonresponders during antidepressant therapy can have a significant impact on improving this situation. Biosignatures predicting antidepressant response a priori or early in treatment would enable an evidence-based decision making on available treatment options. However, research to date does not identify any biologic or genetic predictors of sufficient clinical utility to inform the selection of specific antidepressant compound for an individual patient. In this review, we propose an optimized translational research strategy to overcome some of the major limitations in biomarker discovery. We are confident that early transfer and integration of data between both species, ideally leading to mutual supportive evidence from both preclinical and clinical studies, are most suitable to address some of the obstacles of current depression research.
    Full-text · Article · Jul 2013 · Disease markers
  • Source
    • "Taken together, these data suggest that the brain pharmacokinetics of certain compounds may differ between single knockout abcb1a (-/-) mice and double knockout abcb1ab (-/-) mice. Furthermore, the data from Uhr and co-workers were from a single time point (1 h) following fluoxetine administration (Uhr et al., 2000); Doran and colleagues, on the other hand, took samples at various time points (Doran et al., 2005). Therefore, the impact of P-gp on fluoxetine distribution may be time- dependent. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The drug efflux pump P-glycoprotein (P-gp) plays an important role in the function of the blood-brain barrier by selectively extruding certain endogenous and exogenous molecules, thus limiting the ability of its substrates to reach the brain. Emerging evidence suggests that P-gp may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. Despite some inconsistency in the literature, clinical investigations of potential associations between functional single nucleotide polymorphisms in ABCB1, the gene which encodes P-gp, and antidepressant response have highlighted a potential link between P-gp function and treatment-resistant depression (TRD). Therefore, co-administration of P-gp inhibitors with antidepressants to patients who are refractory to antidepressant therapy may represent a novel therapeutic approach in the management of TRD. Furthermore, certain antidepressants inhibit P-gp in vitro, and it has been hypothesized that inhibition of P-gp by such antidepressant drugs may play a role in their therapeutic action. The present review summarizes the available in vitro, in vivo and clinical data pertaining to interactions between antidepressant drugs and P-gp, and discusses the potential relevance of these interactions in the treatment of depression.
    Full-text · Article · Jun 2011 · British Journal of Pharmacology
Show more